Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes

a cohort profile

Diana Hedevang Christensen, Sia Kromann Nicolaisen, Klára Berencsi, Henning Beck-Nielsen, Jørgen Rungby, Søren Friborg, Ivan Brandslund, Jens Sandahl Christiansen, Allan Vaag, Henrik Toft Sørensen, Jens Steen Nielsen, Reimar Wernich Thomsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

75 Downloads (Pure)

Resumé

Purpose The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrols newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis. Participants Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip-waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at â '80°C and currently analysed for a range of biomarkers and genotypes. Findings to date Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported. Future plans During 2016, a detailed follow-up questionnaire has been answered by 85% of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.

OriginalsprogEngelsk
Artikelnummere017273
TidsskriftBMJ Open
Vol/bind8
Udgave nummer4
Antal sider11
ISSN2044-6055
DOI
StatusUdgivet - 1. apr. 2018

Fingeraftryk

Type 2 Diabetes Mellitus
Research
Diabetes Complications
Albuminuria
Diabetic Neuropathies
Glycosylated Hemoglobin A
Denmark
Alcohol Drinking
Habits
Registries
Primary Health Care
Body Mass Index
Smoking
Clinical Trials
Urine
Interviews
Exercise
Lipids
DNA
Neoplasms

Citer dette

Christensen, Diana Hedevang ; Nicolaisen, Sia Kromann ; Berencsi, Klára ; Beck-Nielsen, Henning ; Rungby, Jørgen ; Friborg, Søren ; Brandslund, Ivan ; Christiansen, Jens Sandahl ; Vaag, Allan ; Sørensen, Henrik Toft ; Nielsen, Jens Steen ; Thomsen, Reimar Wernich. / Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes : a cohort profile. I: BMJ Open. 2018 ; Bind 8, Nr. 4.
@article{af686286d2ef4b32b9cdf666c3df2371,
title = "Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile",
abstract = "Purpose The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrols newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis. Participants Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip-waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at {\^a} '80°C and currently analysed for a range of biomarkers and genotypes. Findings to date Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported. Future plans During 2016, a detailed follow-up questionnaire has been answered by 85{\%} of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.",
keywords = "epidemiology, general diabetes, genetics",
author = "Christensen, {Diana Hedevang} and Nicolaisen, {Sia Kromann} and Kl{\'a}ra Berencsi and Henning Beck-Nielsen and J{\o}rgen Rungby and S{\o}ren Friborg and Ivan Brandslund and Christiansen, {Jens Sandahl} and Allan Vaag and S{\o}rensen, {Henrik Toft} and Nielsen, {Jens Steen} and Thomsen, {Reimar Wernich}",
note = "{\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2018",
month = "4",
day = "1",
doi = "10.1136/bmjopen-2017-017273",
language = "English",
volume = "8",
journal = "B M J Open",
issn = "2044-6055",
publisher = "BMJ Group",
number = "4",

}

Christensen, DH, Nicolaisen, SK, Berencsi, K, Beck-Nielsen, H, Rungby, J, Friborg, S, Brandslund, I, Christiansen, JS, Vaag, A, Sørensen, HT, Nielsen, JS & Thomsen, RW 2018, 'Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile', BMJ Open, bind 8, nr. 4, e017273. https://doi.org/10.1136/bmjopen-2017-017273

Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes : a cohort profile. / Christensen, Diana Hedevang; Nicolaisen, Sia Kromann; Berencsi, Klára; Beck-Nielsen, Henning; Rungby, Jørgen; Friborg, Søren; Brandslund, Ivan; Christiansen, Jens Sandahl; Vaag, Allan; Sørensen, Henrik Toft; Nielsen, Jens Steen; Thomsen, Reimar Wernich.

I: BMJ Open, Bind 8, Nr. 4, e017273, 01.04.2018.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes

T2 - a cohort profile

AU - Christensen, Diana Hedevang

AU - Nicolaisen, Sia Kromann

AU - Berencsi, Klára

AU - Beck-Nielsen, Henning

AU - Rungby, Jørgen

AU - Friborg, Søren

AU - Brandslund, Ivan

AU - Christiansen, Jens Sandahl

AU - Vaag, Allan

AU - Sørensen, Henrik Toft

AU - Nielsen, Jens Steen

AU - Thomsen, Reimar Wernich

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrols newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis. Participants Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip-waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at â '80°C and currently analysed for a range of biomarkers and genotypes. Findings to date Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported. Future plans During 2016, a detailed follow-up questionnaire has been answered by 85% of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.

AB - Purpose The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrols newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis. Participants Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip-waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at â '80°C and currently analysed for a range of biomarkers and genotypes. Findings to date Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported. Future plans During 2016, a detailed follow-up questionnaire has been answered by 85% of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.

KW - epidemiology

KW - general diabetes

KW - genetics

U2 - 10.1136/bmjopen-2017-017273

DO - 10.1136/bmjopen-2017-017273

M3 - Journal article

VL - 8

JO - B M J Open

JF - B M J Open

SN - 2044-6055

IS - 4

M1 - e017273

ER -